Introduction {#s1}
============

Mutations in ribosomal proteins (RPs) often have distinct phenotypes and, in people, they lead to diseases called ribosomopathies ([@bib8]; [@bib22]; [@bib31]; [@bib69]). How perturbations of a general process such as protein synthesis can lead to specificity in the observed phenotypes is puzzling. Specialized ribosomes with different composition may account for the distinct phenotypes of ribosomal protein mutants ([@bib85]; [@bib105]). In another scenario, in Diamond-Blackfan anemia patients carrying mutations in several ribosomal proteins, a lower ribosome content alters the translation of mRNAs critical for hematopoiesis ([@bib48]). In yeast, lower ribosome levels may lead to dose-dependent changes in gene expression that parallel the overall growth rate ([@bib16]). A kinetic model of translation proposed that specificity could arise from disproportional effects on translational efficiency of specific mRNAs when the ribosome content in the cell changes ([@bib61]; [@bib69]). Overall, to understand how ribosomal protein mutants have distinct phenotypes, it is necessary to identify the relevant mRNAs with altered translational control, and then link the corresponding gene products to the observed phenotypes.

In budding yeast, 15 out of a total of 79 cytoplasmic ribosomal proteins are not essential ([@bib92]). Pairs of similar paralogs encode 59 of the ribosomal proteins ([@bib101]). In most cases, cells lacking one of the two paralogs encoding a ribosomal protein are viable ([@bib30]; [@bib92]). Interfering with ribosome biogenesis usually affects cell cycle progression dramatically, but not uniformly across different ribosome biogenesis mutants ([@bib33]; [@bib38]; [@bib49]; [@bib93]). For example, loss of Rpl22Bp does not lengthen the G1 phase of the cell cycle, while the loss of Rpl22Ap does ([@bib33]; [@bib38]; [@bib98]). Dysregulation of translation is also strongly linked with aging. The number of times a yeast cell can divide and generate daughter cells defines its replicative lifespan ([@bib91]). Protein synthesis is dysregulated in aged cells, and it is thought to be a driver of aging ([@bib42]). Mutations in ribosomal proteins of the large (60S) subunit constitute a significant class of pro-longevity mutations in yeast and other species ([@bib45]; [@bib44]; [@bib64]; [@bib90]; [@bib92]). The *rpl* association with longevity, however, is often paralog-specific and complex. For example, the Rpl22 double paralog deletion is viable, but not long-lived ([@bib92]). The single *rpl22aΔ* mutants is long-lived, but *rpl22b∆* cells are not long-lived ([@bib92]). In other ribosomal proteins, e.g., Rpl34, loss of either of the Rpl34 paralogs promotes longevity ([@bib92]). Importantly, bulk inhibition of translation with cycloheximide at various doses does *not* increase lifespan ([@bib90]). The above observations argue that simple relations between ribosome content, protein synthesis capacity, or generation time cannot sufficiently explain the longevity of *rpl* paralog mutants. To account for these paralog-specific phenotypes, we decided to identify patterns of translational control that are specific to paralogous ribosomal proteins and responsible for the increased longevity and altered cell cycle progression of *rpl* mutants.

Here, we identified changes in gene expression and metabolite levels that explain the differential longevity of Rpl22 paralog mutants. We show that translational control of enzymes involved in one-carbon metabolic pathways underpins replicative lifespan. Loss-of-function mutations in enzymes of these metabolic pathways extended the lifespan of otherwise wild type cells, underscoring the physiological relevance of our findings. Given the broad conservation of these pathways in other organisms, including humans, our results could have significant implications for longevity interventions.

Results {#s2}
=======

Rationale and experimental overview {#s2-1}
-----------------------------------

Based on recent elegant studies ([@bib16]; [@bib48]), lower ribosome levels and the accompanying longer generation times could underlie some of the phenotypes of ribosomal protein mutants. Hence, we first examined if generation time is associated with the replicative lifespan of *rpl* mutants. A weak, positive association had been reported between the change in mean lifespan in *rpl* mutants and their generation time relative to wild type cells ([@bib90]). Because ribosomal protein mutants often accumulate suppressors, we re-examined the association between lifespan and generation time using data from the fresh, recreated collection of all of the single ribosomal protein deletions ([@bib64]; [@bib92]). We also examined the relationship between lifespan and ribosomal protein abundance, using the latest consensus estimates of protein abundances in yeast ([@bib37]). We found no significant association between the lifespan of *rpl* mutants with either their generation time (ρ = −0.02, based on the non-parametric, Spearman rank correlation coefficient), or the levels of the corresponding Rpl protein in wild type cells (ρ = −0.06; [Figure 1](#fig1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Therefore, the general effects on generation time from ribosomal protein loss cannot adequately explain the longevity phenotypes of *rpl* mutants.

![Doubling time and normal Rpl levels are not associated with the replicative lifespan of single *rpl* deletion mutants.\
(**A**) Scatterplot between the generation time (x-axis; from Tables S2 in [@bib92]) and replicative lifespan (y-axis; as percentage of the wild type lifespan, from Table 3 in [@bib92] and Table S2 in [@bib64]). (**B**) Scatterplot between the abundance of each deleted Rpl typically found in wild type cells (x-axis; the median number of molecules per cell, from Table S4 from [@bib37]) and replicative lifespan (y-axis; as percentage of the wild type lifespan, from Table 3 in [@bib92] and Table S2 in [@bib64]). The Spearman correlation coefficients (ρ) shown in each case were calculated with the rcorr function of the *Hmisc* R language package, comparing the pair shown in each panel. All the values used as input for this figure and analyses are in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
Figure 1---source data 1.Lifespan, doubling time, and RP levels in ribosomal protein mutants.](elife-53127-fig1){#fig1}

Ribosome composition is largely unaffected in *rpl22* mutants {#s2-2}
-------------------------------------------------------------

To identify the molecular basis for the paralog-specific *rpl* phenotypes, we focused primarily on the Rpl22Ap and Rpl22Bp pair. We chose Rpl22 because there are phenotypes of interest seen in *rpl22aΔ* but not in *rpl22bΔ* cells: First, *rpl22aΔ* cells have a consistently longer replicative lifespan (≈38%) than wild type, or *rpl22bΔ,* cells ([@bib92]). Second, *rpl22aΔ* cells have a longer G1 phase due to small birth size and a lower rate of size increase ([@bib33]). Third, *rpl22aΔ* cells are also more sensitive to oxidative stress ([@bib15]).

We asked if the proportion of ribosomal proteins in assembled ribosomes changes significantly in *rpl22* deletion mutants. To this end, we isolated ribosomes through sucrose ultra-centrifugation from wild type, *rpl22aΔ*, *rpl22bΔ* or double *rpl22a,bΔ* cells ([@bib92]), which were otherwise in the same isogenic haploid background ([Figure 2A](#fig2){ref-type="fig"}; see Materials and methods). We queried each strain in three independent replicates. Ribosomal protein abundance was measured with SWATH-mass spectrometry (see Materials and methods). We confirmed that in wild type (WT) cells, the levels of Rpl22Ap are much higher (\>10 fold; [Figure 2B](#fig2){ref-type="fig"}) than Rpl22Bp (see also [@bib37]). In *rpl22aΔ* cells, there is a compensatory (≈5-fold) increase in the levels of Rpl22Bp, but the total Rpl22 levels are still significantly lower (≈2 to 3-fold) than in wild type cells ([Figure 2B](#fig2){ref-type="fig"}). A similar compensatory change in Rpl22 paralog expression exists in mice ([@bib72]).

![Loss of Rpl22 does not affect the relative abundance of other ribosomal proteins in ribosomes.\
(**A**) Schematic overview of the approach to query ribosomal protein abundances in *rpl22* deletion mutants (see Materials and methods). All strains were in the haploid BY4742 background. The doubling time values for each strain are shown on top (Td; in min, from Table S2 in [@bib92]). (**B**) Bar plot displaying on the x-axis the levels of Rpl22Ap and Rpl22Bp in wild type and *rpl22* deletion mutants, as indicated on the y-axis. The abundances shown correspond to the peak area intensities obtained from SWATH-MS (see Materials and methods and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). (**C**) The Log2-transformed ratios of the intensities corresponding to the ribosomal proteins detected are indicated for each pairwise comparison among the 4 strains we analyzed. Changes higher than 2-fold are outside the dashed red lines in each panel. Note that not all the changes were statistically significant, as indicated. The red arrows indicate the only cases where the differences were significant (Log2FC ≥ 1 and p-value\<0.05; bootstrap-based ANOVA; see Materials and methods) The Spearman correlation coefficients (ρ) shown in each case were calculated with the rcorr function of the *Hmisc* R language package, comparing the pair shown in each panel.\
Figure 2---source data 1.SWATH-mass spectrometry measurements of ribosomal protein abundances.](elife-53127-fig2){#fig2}

Next, we looked at the abundance of all other ribosomal proteins we could identify with SWATH-mass spectrometry ([Figure 2C](#fig2){ref-type="fig"}). Other than Rpl22 itself, the only RPs with statistically significant differences higher than 2-fold among the four strains (indicated with the red arrows in [Figure 2C](#fig2){ref-type="fig"}) was Rpp2Bp (a stalk protein that does not interact with rRNA and may have been lost during ribosome isolation) and Rps9p (in only one binary comparison). In all strains tested, including the *rpl22a,bΔ* cells lacking Rpl22 altogether, the relative proportion of the RPs in ribosomes was essentially constant, indicated by the Spearman rank correlation coefficients (ρ), which were very high (≥0.95) in each case. Hence, at least based on these population-averaged measurements, other than Rpl22 itself, the ribosomal composition seems unaffected by the loss of one or both of the Rpl22 paralogs.

Loss of Rpl22Ap reduces overall protein synthesis {#s2-3}
-------------------------------------------------

To quantify overall protein synthesis in wild type, *rpl22aΔ*, *rpl22bΔ* or double *rpl22a,bΔ* cells, we measured incorporation of the methionine analog L-homo-propargylglycine (HPG) into newly synthesized proteins ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). After the incorporated HPG was chemically modified to fluoresce (see Materials and methods), the fluorescence per cell was recorded by flow cytometry ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). The cells were also imaged by microscopy ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). Both *rpl22aΔ* and *rpl22a,bΔ* cells had similar and significantly reduced (≈2-fold) HPG incorporation compared to wild type or *rpl22bΔ* cells ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Because *rpl22a,bΔ* cells are not long-lived ([@bib92]), we conclude that merely reducing rates of protein synthesis is not sufficient to promote longevity. This conclusion is in agreement with the observation that inhibiting protein synthesis with cycloheximide also does not increase lifespan ([@bib90]). Hence, translational effects responsible for the longevity of *rpl22aΔ* cells probably involve more nuanced and specific outputs, not reflected by bulk impacts on protein synthesis ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}) or cell generation time ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}).

Generating RNAseq and Riboseq libraries from synchronous, dividing cells lacking ribosomal protein paralogs {#s2-4}
-----------------------------------------------------------------------------------------------------------

Ribosomal protein mutants often have distinct cell cycle phenotypes, even when their generation time is similar ([@bib33]). To capture translational effects in the different ribosomal protein paralog mutants that might be cell cycle-dependent, and difficult to discern from asynchronous cultures, we made our RNA libraries for ribosome profiling from highly synchronous cultures. We used centrifugal elutriation to obtain our synchronous cultures of ribosomal protein paralog mutants. Unlike arrest-and-release synchronization approaches, centrifugal elutriation maintains as much as possible the normal coupling of cell growth with cell division ([@bib7]; [@bib88]). To collect enough cells for these experiments, we followed the same approach as in our previous work on wild type cells ([@bib10]). Briefly, for each mutant strain, elutriated G1 cells were allowed to progress in the cell cycle until they reached the desired cell size, at which point they were frozen away, and later pooled with cells of similar size ([Figure 3A](#fig3){ref-type="fig"}). In this manner, we collected enough cells to generate a cell size-series for each ribosomal protein mutant, spanning a range from 40 to 75 fL, sampled every 5 fL intervals in three biological replicates in each case ([Figure 3B](#fig3){ref-type="fig"}). Note that for these experiments, we used homozygous diploid strains lacking Rpl22Ap, Rpl22Bp, Rpl34Ap, or Rpl34Bp, for two reasons: First, to minimize the possible effects of recessive suppressors. Second, so that these datasets could be compared to a similar dataset we generated from the parental diploid wild type cells ([@bib10]).

![Querying synchronous, dividing cells lacking ribosomal protein paralogs.\
(**A**) Schematic of our experimental approach to identify gene expression changes in *rpl22* and *rpl34* paralog mutants at the transcriptional or translational level, from cells at several different stages of the cell cycle. (**B**) Cell size (in fL, x-axis) and the percentage of budded cells (%Budded, y-axis) from each pool of the indicated strains. The values shown are the weighted averages, from the different elutriated samples in each pool. (**C**) On the y-axis, are the Log2-transformed TPM values from representative transcripts known to increase in abundance in S (histone H4; *HHF1*), G2 phase (cyclin *CLB2*), or are constitutively expressed (*ACT1*). Cell size is on the x-axis.\
Figure 3---source data 1.Raw read sequencing data.\
Figure 3---source data 2.TPM-normalized sequencing data.](elife-53127-fig3){#fig3}

Budding coincides with the initiation of DNA replication and exit from the G1 phase in *S. cerevisiae* ([@bib32]; [@bib75]; [@bib79]). Hence, we scored by microscopy the percentage of budded cells across each cell size series ([Figure 3B](#fig3){ref-type="fig"}), to gauge the synchrony we obtained. In every case, the pools of the smallest size (40 fL) were unbudded, rising steadily to \>80% budded at the largest cell size (75 fL). The cell size at which half the cells are budded is often called the 'critical' size, serving as a convenient proxy for the commitment step START ([@bib38]). All four ribosomal protein mutants had a critical size of ≈60--65 fL ([Figure 3B](#fig3){ref-type="fig"}), which is similar to the critical size obtained from typical time-series elutriation experiments for wild type, *rpl22aΔ/rpl22aΔ*, or *rpl34aΔ/rpl34aΔ* cells we had reported previously ([@bib33]). From the RNAseq data that we will describe later ([Figure 4](#fig4){ref-type="fig"}), transcripts that are known to increase in abundance in S (histone H4; *HHF1*), or G2 phase (cyclin *CLB2*), peaked as expected in the cell size series ([Figure 3C](#fig3){ref-type="fig"}). Overall, based on morphological ([Figure 3B](#fig3){ref-type="fig"}) and molecular ([Figure 3C](#fig3){ref-type="fig"}) markers of cell cycle progression, the synchrony of all the cell size series was of good quality. Note that our cell size series did not necessarily reflect the entire cell cycle. For example, *rpl22aΔ/rpl22aΔ* cells stay longer in the G1 phase because they are born smaller and also grow in size slower ([@bib33]). Nonetheless, for any given cell size, the datasets we generated are directly comparable among the different strains, even though the cell cycle length of these strains may not be the same.

![Transcripts with altered relative abundance in *rpl22* and *rpl34* paralog deletion mutants.\
(**A**) Decision diagram for identifying transcripts that were differentially expressed in paralog deletion mutants. (**B**) The number of transcripts with significantly different levels (adjusted p-value/FDR \< 0.05, Log2FC ≥ 2, identified both from the *babel* and *DESeq2* R language packages) at any one cell size pool, between any pairwise comparison between WT, *rpl22*, and *rpl34* mutants is shown. The data for wild type diploid cells were from [@bib10]. The Gene Ontology terms ([@bib94]) that were most enriched in each case are shown, based on the PANTHER ([@bib68]) platform classification, incorporating the Holm-Bonferroni correction. All the gene names of loci with significant changes in transcript levels are in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"} (sheet 'cumulative'). The 'UP' and 'DOWN' groupings correspond to each pairwise comparison shown, with the 'UP', or 'DOWN', group higher, or lower, for the strain in the numerator of the ratio, respectively. (**C**) Reduced levels of transcripts encoding glycolytic/gluconeogenic enzymes in *rpl22aΔ* compared to *rpl22bΔ* cells. The Log2-transformed ratio of the corresponding TPM values is shown in each case, across the different cell size pools. The data were hierarchically clustered without supervision and displayed with the *pheatmap* R package. Each row corresponds to a separate 5 fL cell size interval, from 40 to 75 fL, from top to bottom. The arrows indicate transcripts for key enzymes of glycolysis and gluconeogenesis. mRNAs with missing values across the cell sizes we analyzed were not included in the heatmap.\
Figure 4---source data 1.mRNAs with significantly different abundances between any two strains.](elife-53127-fig4){#fig4}

From the samples described above, we prepared 96 ribosome footprint libraries (24 per ribosomal protein mutant) and the corresponding, sample-matched 96 RNA libraries. The libraries were constructed as described in our previous work for the wild type cells ([@bib10]), with one significant exception. Here, we used rRNA subtraction for the RNA libraries, because it has since been reported that polyA-selected RNA might introduce bias in the quantification of the transcript abundances ([@bib103]). The sequences were mapped as we describe in Materials and Methods. Using the same mapping pipeline, we re-mapped our published reads from the wild type cells as well ([@bib10]). Together, these datasets comprise 120 ribosome footprint libraries and the matching 120 transcript libraries, used as input in all our subsequent analyses described in this report (see [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}).

Transcripts with altered relative abundance in *rpl22* and *rpl34* mutants {#s2-5}
--------------------------------------------------------------------------

To identify differentially expressed mRNAs, we examined all ten pairwise comparisons among the *rpl22* and *rpl34* deletion mutants and wild type cells. In our computational pipeline (see [Figure 4A](#fig4){ref-type="fig"}, and Materials and methods), only ORFs with ≥20 reads were included. We used two different, R language-based packages, *babel*, and *DESeq2*, in each analysis. Candidate mRNAs with differential expression between two strains, at any one point in the cell cycle, had an adjusted p-value or false discovery rate (FDR) of \<0.05 in *both* analyses, and a fold-change ≥4. Lastly, transcripts of the highest priority were those enriched in a gene ontology category (p\<0.05, incorporating the Holm Bonferroni correction). Overall, at the transcript abundance level, no process was uniformly upregulated in the ribosomal protein mutants ([Figure 4B](#fig4){ref-type="fig"}, left). However, from all pairwise comparisons, two significant patterns emerge: First, the only process that was downregulated transcriptionally in *rpl* paralog mutants was cytoplasmic translation itself ([Figure 4B](#fig4){ref-type="fig"}, right). Second, when comparing paralog deletions of the same ribosomal protein (i.e., *rpl22aΔ* vs. *rpl22bΔ*; or *rpl34aΔ* vs. *rpl34bΔ*), there were few significant changes, compared to any other pairwise comparison. There was no gene ontology enrichment between the Rpl34 paralog deletions ([Figure 4B](#fig4){ref-type="fig"}). We noticed, however, that compared to *rpl22bΔ* cells, *rpl22aΔ* cells had significantly reduced (p=4.9E-04) levels of transcripts encoding enzymes of glycolysis and gluconeogenesis ([Figure 4C](#fig4){ref-type="fig"}): Tdh1p is glyceraldehyde-3-phosphate dehydrogenase; Eno1p is enolase; Fbp1 is fructose-1,6-bisphosphatase; Pck1p is phosphoenolpyruvate carboxykinase. These data suggest that compared to cells lacking Rpl22Bp, the central pathway of glycolysis/gluconeogenesis may be downregulated in cells lacking Rpl22Ap.

Transcripts with altered relative translational efficiency in *rpl22* and *rpl34* mutants {#s2-6}
-----------------------------------------------------------------------------------------

To identify mRNAs with altered translational efficiency between the strains we queried, we relied again on multiple computational pipelines ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}, see Materials and Methods). Transcripts whose translational efficiency (i.e., the ratio of ribosome-bound to total mRNA abundance) was different between two strains, at any one point in the cell cycle, with an adjusted p-value or false discovery rate (FDR) of \<0.05 in *all* three analyses, and a fold-change ≥2, were categorized as 'positive'. Our strategy of relying on multiple computational approaches to identify mRNAs under translational control in the various strains we analyzed may be very stringent in some cases, missing true positives. For example, *GCN4* was identified in several comparisons by one or more (see [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}), but not all three of the computational pipelines we used. *GCN4* encodes a bZIP transcriptional activator of amino acid biosynthetic genes, whose expression responds to amino acid starvation. In wild type cells growing in nutrient-rich conditions, translation of *GCN4* is repressed by uORFs that impede ribosomes from initiating Gcn4p synthesis, while in poor nutrients, translation of *GCN4* is de-repressed ([@bib36]). It is also known that the long-lived *rpl31aΔ* and *rpl20bΔ* ribosomal mutants have higher levels of Gcn4p ([@bib90]). Furthermore, Gcn4p is required for the full increase in longevity of *rpl* mutants ([@bib90]), and overexpression of Gcn4p can extend replicative lifespan without changes in bulk protein synthesis ([@bib39]). As we mentioned above, in pairwise strain comparisons *GCN4* was not identified by all computational approaches we used (see [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). However, when examined in each strain against all other mRNAs of that strain, the translational efficiency of *GCN4* was significantly reduced in wild type and *rpl22bΔ* cells, but not in the long-lived *rpl22aΔ* cells ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), as expected from the results of [@bib90]. Overall, despite missing some target mRNAs, based on the data we will present next, the multiple computational pipelines of our approach yield robust, physiologically relevant datasets.

Based on ontology enrichment from the mRNAs we identified, we observed the following: First, compared to wild type cells, each *rpl* paralog mutant had upregulated the translational efficiency of mRNAs encoding gene products involved in cytoplasmic translation ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"} and [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Cheng et al reported recently a similar phenomenon in *rps* mutants, but not in the *rpl* mutants they analyzed, which did not include *rpl22* or *rpl34* ([@bib16]). Hence, our results may reflect a more general response in *rp* mutants, including of the large 60S subunit, to compensate for their dysfunctional protein synthesis. Second, relative to wild type, the *rpl34aΔ*, and *rpl34bΔ*, paralog deletions had reduced translational efficiency of one-carbon ([Figure 5---figure supplement 3C](#fig5s3){ref-type="fig"}), and amino-acid ([Figure 5---figure supplement 3D](#fig5s3){ref-type="fig"}), metabolic pathways, respectively. The down-regulation of mRNAs encoding 1C enzymes in *rpl34aΔ* cells is consistent with the hypothesis that down-regulation of 1C metabolism is associated with increased longevity, as we will describe later in the manuscript. Third, as was the case for the transcriptomic comparisons ([Figure 4B](#fig4){ref-type="fig"}), the smallest number of mRNAs with altered translational efficiency was observed when comparing paralog deletions of the same ribosomal protein (i.e., *rpl22aΔ* vs. *rpl22bΔ*; or *rpl34aΔ* vs. *rpl34bΔ*). For the *rpl34aΔ* vs. *rpl34bΔ* comparison, there was no enrichment for any particular group ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), consistent with the fact that the *rpl34* paralog mutants have similar phenotypes, both being long-lived. Fourth, compared to *rpl22bΔ* cells, *rpl22aΔ* cells had significantly reduced (p=2.93E-02) translational efficiency of transcripts encoding enzymes of serine and methionine metabolism, which are part of what is collectively known as one-carbon metabolic pathways ([Figure 5B](#fig5){ref-type="fig"}). We will expand more on the latter result in subsequent sections.

![Reduced translational efficiency of transcripts encoding enzymes of the methionine and 1C metabolic pathways in *rpl22aΔ* cells.\
(**A**) Heatmap of the transcripts with significantly different translational efficiencies (see [Figure 3](#fig3){ref-type="fig"}) between the two Rpl22 paralog deletion strains. The ratio of the TPM values for the ribosome footprints ((ribo) against the corresponding values for the mRNA reads (rna) define the translational efficiency of each locus in each paralog mutant. The data were hierarchically clustered and displayed with the *pheatmap* R package. Each row corresponds to a separate cell size interval, from 40 to 75 fL, from top to bottom. The Gene Ontology terms highlighted were enriched, based on the PANTHER platform classification, incorporating the Holm-Bonferroni correction. (**B**) Diagram of the metabolic pathways involving enzymes whose mRNAs have altered translational efficiency in *rpl22aΔ* vs *rpl22bΔ* cells. Proteins whose mRNAs have lower translational efficiency in *rpl22aΔ* cells are shown in blue. (**C**) Immunoblots from WT (*RPL22^+^*), *rpl22aΔ,* or *rpl22bΔ* cells, carrying a *MET3-TAP* allele expressed from its endogenous chromosomal location. All the strains were otherwise isogenic. The signal corresponding to Met3p-TAP was detected with the PAP reagent, while the Pgk1p signal represents loading. The band intensities were quantified using the ImageJ software package, and the relative abundance of Met3p-TAP in *rpl22aΔ: rpl22bΔ* cells is shown at the bottom, from three independent such experiments.\
Figure 5---source data 1.mRNAs with significantly different translational efficiency between any two strains.](elife-53127-fig5){#fig5}

Lastly, we looked at mRNA features of translationally controlled mRNAs. For each mRNA with altered translational efficiency, we examined the lengths of the ORF, its 5'-leader, and its 5'-UTR ([@bib59]). We also looked at the abundance of the corresponding protein ([@bib37]). We grouped all the mRNAs with altered translational efficiency in any of the *rpl* deletions compared to wild type ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}, top), and we also compared mRNAs with differential translation between *rpl22aΔ* vs. *rpl22bΔ* cells ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}, bottom). Overall, there were statistically significant differences, but the magnitude of the differences was not particularly striking ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). One general feature seems to be that mRNAs that encode for relatively abundant proteins were among those that were translationally controlled (either up or downregulated) in the WT vs. *rpl* comparisons and also in *rpl22aΔ* vs. *rpl22bΔ* cells (in this case, for the downregulated group; [Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}).

The differences between *rpl34aΔ* vs. *rpl34bΔ* both in the abundance of mRNAs ([Figure 4B](#fig4){ref-type="fig"}) and in their translational efficiency ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) were few and without any significant enrichment in any gene ontology group. These observations are consistent with the similar phenotypes observed in *rpl34aΔ* and *rpl34bΔ* cells, which both have a longer replicative lifespan ([@bib92]), and with the notion that longevity is associated with altered translational efficiency of specific mRNAs. Hence, for the remainder of this study, we focused instead on the comparison between *rpl22aΔ* vs. *rpl22bΔ*, using the molecular information we generated to explain the different phenotypes of the *rpl22* paralog pair of deletion mutants.

Translational control of methionine and serine metabolic pathways in *rpl22aΔ* cells {#s2-7}
------------------------------------------------------------------------------------

Among the transcripts with reduced translational efficiency in *rpl22aΔ* vs. *rpl22bΔ* cells ([Figure 5A](#fig5){ref-type="fig"}), the only significantly enriched (17.6-fold, p=2.93E-02) gene ontology group was the 'serine family amino acid metabolic process' (GO:0009069). The group included the mRNAs encoding Shm2p (cytosolic serine hydroxymethyltransferase), Met3p (sulfate adenylyltransferase), Met17p (homocysteine/cysteine synthase), Met5p (sulfite reductase, β subunit), Gcv2p (mitochondrial glycine dehydrogenase, decarboxylating). These enzymes are also part of methionine (Met3,5,17p) and folate (Shm2p, Gcv2p) metabolic pathways, collectively known as one-carbon (1C) metabolism. Additional mRNAs with reduced translational efficiency in *rpl22aΔ* vs. *rpl22bΔ* cells encoded enzymes of these pathways, shown schematically in [Figure 5B](#fig5){ref-type="fig"}. For example, Ade1p (N-succinyl-5-aminoimidazole-4-carboxamide ribotide synthetase) and Ade17p (containing 5-aminoimidazole-4-carboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrolase activities), are required for \'de novo\' purine nucleotide biosynthesis. We were intrigued by these findings because the loss of Met3p in wild type cells is known to extend replicative longevity ([@bib64]), a phenotype shared with loss of Rpl22Ap ([@bib90]; [@bib92]). To confirm that Met3p levels were significantly lower in *rpl22aΔ* vs. *rpl22bΔ* cells, we crossed a strain expressing TAP-tagged Met3p from its endogenous chromosomal location, with either *rpl22aΔ* or *rpl22bΔ* cells. We then evaluated the independent segregants of these crosses by immunoblots ([Figure 5C](#fig5){ref-type="fig"}). We found that cells lacking Rpl22Ap had ≈4--5-fold lower levels of Met3p-TAP compared to cells lacking Rpl22Bp ([Figure 5C](#fig5){ref-type="fig"}), consistent with our ribosome profiling data. Compared to wild type cells (*RPL22^+^* in [Figure 5C](#fig5){ref-type="fig"}), Met3p abundance was lower in *rpl22aΔ* cells, but higher in *rpl22bΔ* ones ([Figure 5C](#fig5){ref-type="fig"}).

Overall, only 52 mRNAs had reduced translational efficiency in *rpl22aΔ* vs. *rpl22bΔ* cells ([Figure 5A](#fig5){ref-type="fig"}). While additional targets may also contribute to the *rpl22aΔ* phenotypes, the one-carbon pathways involved could explain the phenotypic differences between the two Rpl22 paralog deletion mutants ([Figure 5B](#fig5){ref-type="fig"}). Note also that compared to wild type cells, in *rpl34aΔ* cells, the translational efficiency of enzymes of one-carbon metabolism was downregulated ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). In addition to longevity effects attributed to Met3p, reduced expression of enzymes in one-carbon metabolic pathways could account for the longer G1 and slower growth of *rpl22aΔ* cells ([@bib33]). The same pathways are also responsible for the synthesis of glutathione ([Figure 5B](#fig5){ref-type="fig"}), potentially accounting for the sensitivity of *rpl22aΔ* cells to oxidative stress ([@bib15]). As we described above, there were reduced levels of transcripts encoding key enzymes of glycolysis and gluconeogenesis in *rpl22aΔ* vs. *rpl22bΔ* cells ([Figure 4C](#fig4){ref-type="fig"}). Since serine biosynthesis relies on glycolytic intermediates, such as 3-phosphoglycerate ([@bib1]), our transcriptomic and ribosome profiling data argue for the overall downregulation of 'serine family amino acid metabolic process' in *rpl22aΔ* cells. Additional metabolomic data we will present later support this conclusion.

Metabolic profiling of *rpl22* paralog deletion mutants {#s2-8}
-------------------------------------------------------

Our transcriptomic and ribosome profiling datasets suggest reduced expression of enzymes of methionine and serine metabolic pathways in *rpl22aΔ* vs. *rpl22bΔ* cells. If so, then these changes in gene expression may be accompanied by changes in the levels of metabolites that are part of these pathways. To gain a better view of cellular physiology, we measured the levels of primary metabolites and biogenic amines in wild type, *rpl22aΔ*, and *rpl22bΔ* cells, through untargeted, mass spectrometry-based approaches (see Materials and methods). To pinpoint significant metabolic changes, we focused on the metabolites whose levels changed ≥2 fold between any two strains (p\<0.05; based on bootstrapped ANOVA; see Materials and methods), and they were significantly enriched (FDR \< 0.05) for a metabolic pathway (based on the MetaboAnalyst platform [@bib17]). Cells lacking Rpl22Ap have lower levels of metabolites associated with central carbon (glycolysis, gluconeogenesis, pentose phosphate pathway), and amino acid (including glycine, serine, and methionine) metabolic pathways ([Figure 6A,B](#fig6){ref-type="fig"}). Exogenous addition of metabolites associated with the 1C pathways affected in *rpl22aΔ* cells did not suppress the slower growth of these cells on solid media ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). This was not unexpected, given the downregulation of central pathways such as glycolysis and gluconeogenesis ([Figures 4](#fig4){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Lastly, *rpl22aΔ* cells had significantly elevated levels of the secondary metabolite nobiletin ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Nobiletin is a flavonoid made by plants ([@bib9]), and it was presumably present in the rich, undefined medium we used in these experiments, probably in the yeast extract prepared at the end of industrial fermentations. Nobiletin has well-documented antioxidant properties ([@bib99]), which might explain why *rpl22aΔ* cells accumulate it, given that they are sensitive to oxidative stress ([@bib15]). Overall, the metabolite data are in remarkable congruence with our transcriptomic (lower mRNA levels for enzymes in glycolysis and gluconeogenesis; [Figure 4](#fig4){ref-type="fig"}) and ribosome profiling (lower translational efficiency of mRNAs for enzymes in methionine and serine metabolic pathways; [Figure 5](#fig5){ref-type="fig"}) datasets.

![Metabolic profiling indicates reduced flux through central metabolic pathways and the folate cycle in *rpl22aΔ* cells.\
(**A**) Eleven metabolites shown at the bottom had significantly reduced levels in *rpl22aΔ* cells (Log2FC ≥ 1, p\<0.05; based on bootstrapped ANOVA; see Materials and methods) and they were significantly enriched for the metabolic pathways shown to the right (FDR \< 0.05). Pathway enrichment analysis was done with the *MetaboAnalyst* R language package. The metabolites were identified with untargeted, MS-based profiling of primary metabolites and biogenic amines, and targeted amino acid analysis. Metabolites indicated with gray in the Table are part of the pathways shown to the right. (**B**) The Log2-transformed peak intensities from the MS-based profiling of the metabolites shown in A (except Glycine) are on the y-axis. The strains used in the analysis are on the x-axis. (**C**) The Log2-transformed levels (in nmoles) of amino acids, after PTH-derivatization, Edman degradation and HPLC detection, are shown on the y-axis. The red arrows indicate the only amino acids (Gly and Trp) whose levels were significantly lower in *rpl22aΔ* cells (Log2FC ≥ 1, p\<0.05; based on bootstrapped ANOVA; see Materials and Methods). The strains used in the analysis are on the x-axis, and they were in the BY4742 background.\
Figure 6---source data 1.Metabolite and amino acid abundances.](elife-53127-fig6){#fig6}

We followed-up our untargeted metabolite measurements with a targeted, orthogonal approach that measures amino acid levels. We used the highly sensitive, HPLC-based, PTH amino acid analysis ([@bib34]; see Materials and methods). We found that the Gly:Ser ratio and Trp levels are significantly lower in *rpl22aΔ* vs. *rpl22bΔ* cells ([Figure 6C](#fig6){ref-type="fig"}). The low Trp level in *rpl22aΔ* cells is also of interest because, as we have shown previously, lowering Trp levels promotes longevity in wild type cells ([@bib33]).

Genetic interventions in 1C metabolism that extend longevity {#s2-9}
------------------------------------------------------------

Since the expression of enzymes of one-carbon metabolism and the levels of associated metabolites were reduced in the long-lived *rpl22aΔ* cells ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}), we asked if, besides *MET3* ([@bib64]), loss of other genes in the pathway may prolong replicative longevity. *ADE17* and *SHM2* encode 1C enzymes and they were translationally down-regulated in *rpl22aΔ* cells. *ADE2* does not encode a 1C enzyme and its translational efficiency did not change in *rpl22aΔ* vs. *rpl22bΔ* cells. We also tested *shm1Δ* cells, because even though the translational efficiency of *SHM1* was similar in *rpl22aΔ* vs. *rpl22bΔ* cells, Shm1p catalyzes in mitochondria the same reaction that Shm2p does in the cytoplasm. Loss of *ADE2* (encoding phosphoribosylaminoimidazole carboxylase) did not affect replicative lifespan ([Figure 7D](#fig7){ref-type="fig"}). On the other hand, loss of *SHM2*, *ADE17*, or *SHM1* (encoding the mitochondrial serine hydroxymethyltransferase) significantly extended the lifespan of otherwise wild type cells ([Figure 7](#fig7){ref-type="fig"}). We note that loss of Met3p leads to a similar magnitude (≈15%) of lifespan extension ([@bib64]). Interestingly, all three enzymes encoded by these genes, including Ade17p with its 5-aminoimidazole-4-carboxamide ribonucleotide transformylase activity, catalyze folate-dependent reactions ([@bib96]). In contrast, the carboxylase activity of Ade2p is not folate-dependent. These data suggest that genetic interventions in one-carbon metabolic pathways modulate longevity and provide strong support for the physiological relevance of our extensive profiling of long-lived *rpl* mutants.

![Deletion of enzymes of one-carbon metabolic pathways extends replicative lifespan in yeast.\
Survival curves for MATα (BY4742) cells (shown in black), compared to experiment-matched cells (shown in red) lacking *SHM1* (**A**), *SHM2* (**B**), *ADE17* (**C**), *ADE2* (**D**), or *ADE3* (**E**). Mean lifespans are shown in parentheses, along with the number of cells assayed in each case. In the case of *shm1Δ*, *shm2Δ*, *ade17Δ*, and *ade3Δ* cells, the lifespan extension was significant (p\<0.0001; based on the log-rank test).](elife-53127-fig7){#fig7}

To test the extent to which single deletions of 1C enzymes could contribute to longevity independently of *rpl22aΔ* cells, we measured the longevity of *rpl22aΔ* cells in the context of *ade17Δ*, *shm1Δ*, or *shm2Δ* deletions ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). In every case, the mean life span of the double mutants was the same or even somewhat decreased compared to single *rpl22aΔ* mutants ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). The effects did not reach statistical significance (p\>0.05 in the log-rank test). We conclude that loss of 1C enzymes does not further extend the longevity of *rpl22aΔ* cells.

Cell cycle control and 1C metabolic enzymes {#s2-10}
-------------------------------------------

We noticed that for several of the mRNAs with differential translation in *rpl22aΔ* vs. *rpl22bΔ* cells, the effect was cell cycle-dependent. For example, the translational efficiency of *MET3* and *ADE17* is disproportionately reduced early in the cell cycle in *rpl22aΔ* cells ([Figure 5A](#fig5){ref-type="fig"}). *SHM2* is an intriguing case because its translational efficiency appears to be highly cell cycle-dependent in wild type cells, peaking in the G1 phase ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). In our prior analysis of translational control in the cell cycle of wild type cells ([@bib10]), we did not consider *SHM2* of high priority. Although both of the computational pipelines we had used at the time (*babel* and *anota*) identified *SHM2* as translationally controlled (see Dataset 8 in [@bib10]), we had also applied a Fourier transform to identify the most periodic transcripts ([@bib10]). Probably due to irregularities in the *SHM2* pattern (see [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, leftmost panel), the Fourier-based method missed the periodic translational efficiency of *SHM2*. Note that for the data shown in [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, the translational efficiency of *SHM2* is normalized against all the points in the cell cycle within each strain, not across the different strains. Strikingly, with the possible exception of *rpl22bΔ* cells, in all other *rpl* deletions, the translational efficiency of *SHM2* was not periodic, and there was not a peak in the G1 phase ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}).

The roles of 1C pathways in cell division are prominent during DNA replication, but how they impact other phases of cell cycle progression is less clear. Furthermore, we had previously identified cell cycle alterations, specifically during G1 progression, which were associated with replicative longevity ([@bib33]). Since we found that cells lacking 1C metabolic enzymes had increased lifespan ([Figure 7](#fig7){ref-type="fig"}), we next examined cell cycle progression when 1C metabolism was perturbed. We focused on cells lacking both Shm2p and Ade3p, which generate cytoplasmic 5,10-methylenetetrahydrofolate, because these cells were reported to be enlarged ([@bib106]). Cell size changes may be indicative of cell cycle changes, and the enlargement of *shm2Δ, ade3Δ* cells is consistent with a DNA replication delay, analogous to the megaloblastosis observed in folate deficiencies ([@bib21]). We generated double mutant *shm2Δ, ade3Δ* cells, which were viable, but slow-growing ([Figure 8A](#fig8){ref-type="fig"}). With regards to cell size, we confirmed that *shm2Δ, ade3Δ* cells have a larger mean cell size ([Figure 8B](#fig8){ref-type="fig"}, left), but they are born at normal size ([Figure 8B](#fig8){ref-type="fig"}, right). However, the DNA content of *shm2Δ, ade3Δ* mutants was indistinguishable from that of wild type cells ([Figure 8C](#fig8){ref-type="fig"}). Hence, despite their enlargement and slower proliferation, on average, the relative duration of G1 and non-G1 cell cycle phases are not disproportionally affected in *shm2Δ, ade3Δ* cells, arguing for delays at multiple cell cycle phases. To determine whether the larger size of *shm2Δ, ade3Δ* cells resulted from a delayed G1/S transition, resembling mutants lacking G1 cyclins ([@bib11]; [@bib18]), or from a delay later in the cell cycle, we examined synchronous cultures obtained by elutriation. The rate *shm2Δ, ade3Δ* cells increase in size is about half that of wild type cells ([Figure 8D](#fig8){ref-type="fig"}), and the size at which they initiate DNA replication (a.k.a. critical size) is smaller ([Figure 8E](#fig8){ref-type="fig"}). Note that a reduction in the rate of cell size increase is associated with longer replicative longevity ([@bib33]). Despite their smaller critical size, *shm2Δ, ade3Δ* cells have a substantially longer G1 (by \~170%) than wild type cells, because they reach that size much slower. We conclude that early in the cell cycle, cells lacking both Shm2p and Ade3p cannot increase in size fast enough, and their G1 is prolonged. After the G1/S transition, these cells are again delayed, presumably because of insufficient nucleotide pools for DNA replication. Still, during that time, they continue to increase in size, reaching a significantly larger size than that of wild type cells. These results show that perturbations of folate-based 1C pathways impact multiple cell cycle phases but in distinct ways. During G1 progression, the phenotypes of *shm2Δ, ade3Δ* cells are similar to other growth-limited mutants (e.g., ribosomal biogenesis mutants [@bib33]). Later in the cell cycle, they resemble situations when nucleotide pools are depleted (e.g., upon exposure to hydroxyurea) when cells are delayed in the S phase ([@bib87]). Overall, our results point to the distinct impacts of 1C metabolism on cell cycle progression. 1C metabolism not only fulfills the metabolic needs for DNA replication but also supports cellular growth during G1 progression, perhaps accounting for the role of these pathways in cellular longevity.

![Loss of Shm2p and Ade3p impinges on multiple cell cycle phases but in distinct ways.\
(**A**) Double *shm2Δ,ade3Δ* deletion mutants are slow-growing. Two representative tetrad dissections from *shm2Δ* x *ade3Δ* crosses are shown. The yellow diamond indicates the *shm2Δ,ade3Δ* segregants. All the strains used in B-E were segregants from the same *shm2Δ* x *ade3Δ* crosses and, except as indicated, isogenic otherwise. (**B**) Violin plots of the mean and birth size of the indicated strains, calculated from ≥12 asynchronous cultures in each case. The plots were generated with the *lattice* R language package. Significant differences in pair-wise comparisons were indicated by the non-parametric Kruskal-Wallis test, while the p-values shown were for all significant differences based on the posthoc Nemenyi test (performed with the *PMCMR* R language package). (**C**) Representative DNA content histograms from the indicated strains, from at least 10,000 cells and ≥5 independent asynchronous cultures in each case. On the x-axis is fluorescence per cell, while the cell number is on the y-axis. The average and sd of the percentage of cells with unreplicated DNA (%G1) is shown. There were no statistically significant differences among the strains, based on the non-parametric Kruskal-Wallis test. (**D**) The rate of cell size increase (k, in h^−1^, shown on the y-axis) was calculated as described in [@bib88], for the strains shown on the x-axis. Each data point is the average of two technical replicates, from synchronous elutriated cultures. (**E**) The critical size (y-axis) for the strains shown on the x-axis was calculated as described in [@bib88], from the same cultures as in D.](elife-53127-fig8){#fig8}

Discussion {#s3}
==========

In this report, we comprehensively examined paralog-specific, ribosomal protein mutants during cell division. The data we presented is significant for several reasons: First, we demonstrated that specific mRNAs are under translational control in those mutants. Second, the changes in gene expression we described, supported by metabolite measurements, explain the phenotypic differences of cells lacking Rpl22 paralogs. Third, the data underscore the role and physiological relevance of one-carbon metabolic pathways in cell division and longevity. Below, we discuss our results in the broader context of ribosomal protein perturbations and metabolic alterations in cell division and cellular aging.

Accounting for specific phenotypes in ribosomal protein mutants {#s3-1}
---------------------------------------------------------------

There is clear genetic evidence linking some ribosomal proteins to diseases ([@bib22]; [@bib69]). What is less clear, however, is how ribosomal protein mutations contribute to disease. Early in life, ribosomopathies are consistent with hypo-proliferation, such as defective hematopoiesis ([@bib22]). Perhaps paradoxically, later in life, some of these patients are predisposed to cancer ([@bib8]; [@bib22]). Rpl22, a ribosomal protein we focused on in this report for its association with longevity and cell division in yeast, has also attracted a lot of attention in animal systems. For example, 10% of primary human samples of T-cell acute lymphoblastic leukemia have loss-of-function mutations in *RPL22* ([@bib80]). *RPL22* is also mutated in microsatellite-unstable colorectal ([@bib28]), and endometrial cancers ([@bib28]; [@bib71]), at 77%, and 50% frequency, respectively. In mice, the Rpl22 paralogs are *Rpl22* and *Rpl22-like1* (*Rpl22l1*). Mice lacking *Rpl22* are alive, but their αβ lineage of T cells does not develop ([@bib4]; [@bib89]). It turns out that in mice, the loss of *Rpl22* also triggers a compensatory increase in *Rpl22l1* expression ([@bib72]), similar to what we saw in yeast ([Figure 2B](#fig2){ref-type="fig"}). Several models have been proposed to explain the phenotypes of ribosomal protein mutants. These models may not necessarily be exclusive of each other, and we discuss them briefly below.

Ribosomal proteins could have extra-ribosomal, non-translational functions ([@bib100]; [@bib102]). Free ribosomal proteins accumulate when ribosome biogenesis is perturbed, causing nucleolar stress. It has been reported that both Rpl22 and Rpl22l1 have extra-ribosomal, antagonistic functions in the nucleus ([@bib107]). Loss of Rpl22 in mice activates the stress-induced NF-κB pathway, increasing expression of the stemness factor Lin28B, which then leads to cancer ([@bib80]). When ribosome assembly is disrupted, some of the released ribosomal proteins could bind other targets. For example, Rpl5, Rpl11, and Rpl23 have been reported to impinge on the p53 pathway. These ribosomal proteins inhibit an ubiquitin ligase (Mdm2 in mice, Hdm2 in humans) that degrades the p53 protein ([@bib100]). How these effects could lead to cancer is not clear, since the outcome of those extra-ribosomal roles (i.e., stabilization of p53) would be *hypo*-proliferative. In our studies, we did not see any evidence for, or against, extra-ribosomal roles, since we focused on translational outputs. However, we note that at least in the case of *rpl22* mutants in yeast, translational outputs were sufficient to explain phenotypes of *rpl22aΔ* cells ([Figure 5](#fig5){ref-type="fig"}).

How could specific translational effects come about, from perturbations of an abundant and seemingly homogeneous cellular machinery as the ribosome? Impairing ribosomal proteins could alter the composition of active ribosomes ([@bib13]; [@bib24]). Translation of some mRNAs may depend on such specialized ribosomes with different composition, accounting for the distinct phenotypes of ribosomal protein mutants ([@bib85]; [@bib105]). However, the extent to which ribosome specialization could, or is even necessary to, explain the phenotypes of ribosomal protein mutants is unclear ([@bib69]). Our data showing that ribosome composition was not significantly affected in *rpl22* mutants ([Figure 2C](#fig2){ref-type="fig"}) does not support the specialized ribosome hypothesis. Nevertheless, our data also does not necessarily refute the existence of specialized ribosomes because we performed population-averaged measurements. Translational effects specific to some mRNAs could also arise from the non-linear relationship between translational efficiency and the available ribosome content ([@bib61]). Ribosomal protein perturbations reduce the concentration of active ribosomes ([@bib16]; [@bib48]; [@bib90]), which could then disproportionately affect translation of specific transcripts with elements that impede ribosome access to the main start codon of those mRNAs ([@bib48]; [@bib69]).

To identify translational outputs from ribosomal protein perturbations, regardless whether they arise from altered ribosome composition or concentration, the translational effects on each mRNA need to be measured in ribosomal protein mutants, using unbiased, sensitive, genome-wide, ribosome profiling methods ([@bib40]; [@bib65]). To date, two prior studies queried ribosomal protein mutants with ribosome profiling methodology, in human cells ([@bib48]) and yeast ([@bib16]). In both of these studies, specific translational outputs were detected, broadly related to altered ribosome levels, with no evidence for modified ribosome composition. In the yeast study ([@bib16]), there were also patterns of gene expression changes that reflected the doubling time of the ribosomal protein mutants. Overall, altered translational control as a function of ribosome content and, consequently, the growth rate is reasonable ([@bib61]; [@bib69]). In our previous work, we have also invoked these relationships to explain translational control of mRNAs encoding a G1 cyclin ([@bib11]; [@bib78]) and a lipogenic enzyme ([@bib10]). However, as we will discuss next, growth rate-associated changes cannot explain all the *rp* mutant phenotypes. In yeast, it has also been recently questioned whether the growth rate is tightly associated with the ribosome content ([@bib46]; [@bib67]).

Since the longevity of *rpl* mutants is not significantly associated with generation time ([Figure 1](#fig1){ref-type="fig"}, see also [@bib90]), such simple relationships cannot explain the different behavior of *rpl* mutants with regards to longevity. It is also important to note that even when their overall generation time is similarly prolonged, ribosomal protein mutants may be delayed in the cell cycle for different reasons. We have shown that different variables of G1 progression (birth size, rate of size increase, or critical size) are differentially affected in *rp* mutants ([@bib33]; [@bib88]). Hence, using generation time/growth rate as an aggregate metric to classify the behavior of ribosomal protein mutants may mask the different causes that underlie their longer generation time and possibly other phenotypes these mutants may display. A unique aspect of our experiments is that we measured changes in translational efficiency at multiple points during synchronous, unperturbed cell cycle progression ([Figure 3](#fig3){ref-type="fig"}). This approach enabled us to probe at a much higher dynamic range translational outputs and capture cell cycle-dependent changes in translational efficiency. To our knowledge, there is no experimental support for altered levels of ribosomal proteins or ribosomes in the cell cycle ([@bib12]; [@bib26]; [@bib77]; [@bib86]). Therefore, the evidence for the cell cycle-dependent patterns of translational control we described here ([Figure 5](#fig5){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}) and elsewhere ([@bib10]) is consistent with added layers of regulation, distinct from growth rate-dependent changes in ribosome content.

One carbon metabolism in cell division and cellular aging {#s3-2}
---------------------------------------------------------

The pathways of methionine, serine, glycine, and folates, collectively called one-carbon metabolism, have attracted enormous attention due to their involvement in diseases, especially cancer ([@bib25]; [@bib29]; [@bib60]; [@bib70]; [@bib82]). The interest arises from the self-evident role of these folate-mediated transformations (see [Figure 5B](#fig5){ref-type="fig"}) in the biosynthesis of nucleotides (purines and thymidine; making the pathway the original ([@bib27]) and still widely-used chemotherapy target), amino acid homeostasis, epigenetic maintenance (through the methylation units the pathway provides), and redox defense (through the generation of glutathione). The folate cycle has parallel mitochondrial and cytoplasmic reactions ([Figure 5B](#fig5){ref-type="fig"}). One-carbon units enter through serine, glycine, or formate, while the outputs include thymidine, serine, methionine, purines, formate, carbon dioxide, and NAD(P)H ([Figure 5B](#fig5){ref-type="fig"}). The relative contributions of the mitochondrial pathways vs. the cytosolic ones vary, depending on nutrient and proliferation status, and the organism. In animal cells, most of the methionine 1C units originate from mitochondria ([@bib35]), while cytoplasmic serine hydroxymethyltransferase (cSHMT) directs 1C units toward dTMP synthesis ([@bib35]). Mutations in cSHMT are associated with diseases, including certain cancers ([@bib29]).

In yeast, cells regulate the balance of one-carbon flow between the donors by controlling cytoplasmic serine hydroxymethyltransferase (Shm2p) activity ([@bib76]). For example, by monitoring the levels of the 5,10-methylenetetrahydrofolate pool (usually derived from serine), cells can upregulate glycine catabolism for one-carbon generation when 5,10-methylenetetrahydrofolate is limiting or spare the breakdown of serine when glycine is in surplus ([@bib76]). In cells lacking Rpl22Ap, we found that the translational efficiency of *SHM2* ([Figure 5](#fig5){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}) and the Gly:Ser ratios ([Figure 6](#fig6){ref-type="fig"}) are low. These observations are consistent with a low flux through 1C pathways. We also documented a strong cell cycle-dependent control of the translational efficiency of *SHM2*, peaking in late G1 ([Figure 8](#fig8){ref-type="fig"}). Interestingly, an elevation of human cSHMT levels in S phase, specifically the SHMT1 isoform, has also been reported, without a change in *SHMT1* mRNA levels ([@bib5]; [@bib50]).

We note that the cell cycle profile of wild type cells (33% of the cells in G1; [Figure 8C](#fig8){ref-type="fig"}) is not affected at all by the loss of Ade3p or Shm2p (32--33% G1 cells [Figure 8C](#fig8){ref-type="fig"}), and only slightly so by the loss of Shm1p or Ade17p (27--28% G1 cells; not shown). Likewise, the doubling time of single *ade3Δ*, *ade17Δ*, *shm1Δ* or *shm2Δ* cells is similar to the doubling time of wild type cells ([@bib30]; and not shown). However, the double *shm1Δ,shm2Δ* deletion is lethal ([@bib23]), and the double *shm2Δ,ade3Δ* cells proliferate extremely slowly ([Figure 8A](#fig8){ref-type="fig"}). The redundancy of 1C pathways, e.g., with the near identical cytoplasmic and mitochondrial pathways ([Figure 5B](#fig5){ref-type="fig"}), likely accounts for these effects on cell cycle progression. The cell cycle phenotypes we described upon loss of Shm2p and Ade3p ([Figure 8](#fig8){ref-type="fig"}) illustrate the different ways that folate-based 1C pathways can impinge on cell cycle progression. In other words, *shm2, ade3* mutants cannot *grow* fast enough in G1, but once they complete the G1 transition, they cannot *divide* fast enough. What is particularly interesting with the *shm2, ade3* mutants is not that DNA replication is delayed after it is started (leading to larger cell size), but that the cells also monitor folate-based transformations before they decide to initiate a new round of cell division, in the G1 phase. It is not known how the fluxes of the different outputs of folate metabolism change in the cell cycle. Our results argue for dynamic changes in these outputs, as cells transition through the different phases of the cell cycle. It is reasonable to speculate that folate-based reactions may be uniquely positioned to integrate growth cues and nutrient status with cell cycle progression.

Methionine restriction has been known to promote longevity in yeast and animals ([@bib43]; [@bib52]; [@bib53]; [@bib83]). By and large, however, 1C metabolism has not been previously implicated in longevity mechanisms. Consistent with 1C involvement in longevity pathways are recent observations linking the drug metformin with 1C metabolism ([@bib19]; [@bib66]). Metformin is known to promote longevity and is now in clinical trials for those effects (Clinical Trials Identifier: NCT02432287). In this context, our results that loss of core 1C enzymes (Shm1p, Shm2p, Ade17p) increase the mean and maximal lifespan of yeast cells ([Figure 7](#fig7){ref-type="fig"}) provide direct support for a role of folate-dependent metabolism in longevity mechanisms. It is likely that additional long-lived *rpl* mutants may have 1C metabolic alterations, similar to *rpl22aΔ*, since these mutants also display a slower growth rate, longer G1 phase ([@bib33]), and reduced resistance to oxidative stress ([@bib6]; [@bib14]; [@bib73]). With regards to longevity mechanisms, we note that it is only mild perturbations in 1C pathways that extend lifespan, in several contexts (e.g., in the long-lived *ade17Δ*, *shm1Δ*, *shm2Δ*, or *ade3Δ* cells; see [Figure 7](#fig7){ref-type="fig"}). It is also mild, but not severe delays in cell cycle progression that in some cases extend longevity ([@bib33]).

In summary, our integrated transcriptomic, translatomic, and metabolomic datasets pinpoint mechanisms that control the expression of enzymes of methionine and serine metabolic pathways in the cell cycle and replicative longevity. These results explain the phenotypic differences of ribosomal protein paralog mutants and support a broad role for 1C pathways in cell division and cellular longevity.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                 Designation                                                Source or\                                             Identifiers                                                           Additional\
  (species) or\                                                                                            reference                                                                                                                    information
  resource                                                                                                                                                                                                                              
  --------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------ --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------
  Strain, strain background (*S. cerevisiae*)   BY4743                                                     [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *MAT*a/α *his3*Δ*1/his3*Δ*1 leu2*Δ*0/leu2*Δ*0 LYS2/lys2*Δ*0 met15*Δ*0/MET15 ura3*Δ*0/ura3*Δ*0*

  Strain, strain background (*S. cerevisiae*)   32672                                                      [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *rpl22aΔ::KanMX/rpl22aΔ::KanMX*, BY4743 otherwise

  Strain, strain background (*S. cerevisiae*)   35844                                                      [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *rpl22bΔ::KanMX/rpl22bΔ::KanMX*, BY4743 otherwise

  Strain, strain background (*S. cerevisiae*)   30192                                                      [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *rpl34aΔ::KanMX/rpl34aΔ::KanMX*, BY4743 otherwise

  Strain, strain background (*S. cerevisiae*)   31445                                                      [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *rpl34bΔ::KanMX/rpl34bΔ::KanMX*, BY4743 otherwise

  Strain, strain background (*S. cerevisiae*)   BY4742                                                     [@bib92]                                                                                                                     *MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0*

  Strain, strain background (*S. cerevisiae*)   KS976                                                      [@bib92]                                                                                                                     *rpl22aΔ::URA3,* BY4742 otherwise

  Strain, strain background (*S. cerevisiae*)   KS979                                                      [@bib92]                                                                                                                     *rpl22bΔ::URA3,* BY4742 otherwise

  Strain, strain background (*S. cerevisiae*)   KS999                                                      [@bib92]                                                                                                                     *rpl22a,bΔ::URA3,* BY4742 otherwise

  Strain, strain background (*S. cerevisiae*)   BY4741                                                     [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0*

  Strain, strain background (*S. cerevisiae*)   MET3-TAP                                                   Dharmacon                                              YSC1178-202231887                                                     *MET3-TAP::HIS3M × 6*, BY4741 otherwise

  Strain, strain background (*S. cerevisiae*)   HB147                                                      This study                                                                                                                   *rpl22aΔ::URA3*, *MET3-TAP::HIS3M × 6*, BY4741 otherwise

  Strain, strain background (*S. cerevisiae*)   HB171                                                      This study                                                                                                                   *rpl22bΔ::URA3*, *MET3-TAP::HIS3M × 6*, BY4741 otherwise

  Strain, strain background (*S. cerevisiae*)   13403                                                      [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *shm1Δ::KanMX,* BY4742 otherwise

  Strain, strain background (*S. cerevisiae*)   12669                                                      [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *shm2Δ::KanMX,* BY4742 otherwise

  Strain, strain background (*S. cerevisiae*)   16561                                                      [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *ade17Δ::KanMX,* BY4742 otherwise

  Strain, strain background (*S. cerevisiae*)   12384                                                      [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *ade2Δ::KanMX,* BY4742 otherwise

  Strain, strain background (*S. cerevisiae*)   6591                                                       [@bib30]                                               RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093)          *ade3Δ::KanMX,* BY4741 otherwise

  Strain, strain background (*S. cerevisiae*)   NM64                                                       This study                                                                                                                   *MATα, shm2Δ::KanMX, ade3Δ::KanMX, met ^-^, lys^-^*

  Strain, strain background (*S. cerevisiae*)   NM65                                                       This study                                                                                                                   *MATa, shm2Δ::KanMX, ade3Δ::KanMX, met ^-^, lys^-^*

  Strain, strain background (*S. cerevisiae*)   NM66                                                       This study                                                                                                                   *MATα, ade17Δ::KanMX, rpl22aΔ::URA, his^-^, lys^-^, leu^-^*

  Strain, strain background (*S. cerevisiae*)   NM67                                                       This study                                                                                                                   *MATα, shm2Δ::KanMX, rpl22aΔ::URA, his^-^, leu^-^, met^-^*

  Strain, strain background (*S. cerevisiae*)   NM68                                                       This study                                                                                                                   *MATα, shm1Δ::KanMX, rpl22aΔ::URA, his^-^, leu^-^, met^-^*

  Strain, strain background (*S. cerevisiae*)   BW885                                                      This study                                                                                                                   *MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0*

  Other                                         Yeast extract                                              Sigma-Aldrich                                          Y1625                                                                 

  Other                                         Peptone                                                    Sigma-Aldrich                                          P5905                                                                 

  Chemical compound, drug                       Dextrose                                                   Sigma-Aldrich                                          D9434                                                                 

  Chemical compound, drug                       Cycloheximide                                              Calbiochem                                             239763 M                                                              

  Chemical compound, drug                       Sodium azide                                               Sigma-Aldrich                                          S2002                                                                 

  Chemical compound, drug                       Tris(hydroxymethyl)aminomethane                            Sigma-Aldrich                                          252859                                                                

  Chemical compound, drug                       Tris base                                                  Roche                                                  TRIS-RO                                                               

  Chemical compound, drug                       Sodium chloride                                            Sigma-Aldrich                                          S7653                                                                 

  Chemical compound, drug                       Magnesium chloride hexahydrate                             USP                                                    1374248                                                               

  Chemical compound, drug                       DTT                                                        Sigma-Aldrich                                          D0632                                                                 

  Chemical compound, drug                       Triton X-100                                               Sigma-Aldrich                                          T8787                                                                 

  Peptide, recombinant protein                  Turbo DNase I                                              ThermoFisher                                           AM2238                                                                

  Other                                         Glass beads                                                Scientific Industries                                  SI-BG05                                                               

  Other                                         13 × 51 mm polycarbonate centrifuge tubes                  Beckman Coulter                                        349622                                                                

  Chemical compound, drug                       Sucrose                                                    Sigma-Aldrich                                          S0389                                                                 

  Chemical compound, drug                       Phosphate buffered saline (PBS)                            Sigma-Aldrich                                          P4417                                                                 

  Commercial assay or kit                       Click-iT HPG Alexa Fluor 488 Protein Synthesis Assay Kit   ThermoFisher                                           C10428                                                                

  Chemical compound, drug                       DAPI (4\',6-Diamidino-2-Phenylindole, Dihydrochloride)     ThermoFisher                                           D1306                                                                 

  Commercial assay or kit                       Ribo-Zero Magnetic Gold Kit (Yeast)                        Epicentre                                              MRZY1324                                                              

  Commercial assay or kit                       SciptSeq v2 RNA-Seq Library Preparation Kit                Epicentre                                              SSV21124                                                              

  Antibody                                      Peroxidase Anti-Peroxidase (PAP) Soluble Complex           Sigma-Aldrich                                          P1291                                                                 (1:1000)

  Antibody                                      Anti-Pgk1p antibody, rabbit polyclonal                     abcam                                                  ab38007                                                               (1:1000)

  Other                                         NovexWedgeWell4--12% Tris-Glycine gels                     ThermoFisher                                           XP04125                                                               

  Software, algorithm                           MetaboAnalyst                                              <https://www.metaboanalyst.ca/>                        RRID:[SCR_015539](https://scicrunch.org/resolver/SCR_015539)          Web server for statistical, functional and integrative analysis of metabolomics data

  Software, algorithm                           AccuComp Z2                                                Beckman Coulter                                        383550                                                                Software to monitor number and size of cells with Z2 cell counter

  Software, algorithm                           NIS-Elements                                               <https://www.nikoninstruments.com/Products/Software>   RRID:[SCR_014329](https://scicrunch.org/resolver/SCR_014329)          Microscope imaging software suite used with Nikon products

  Software, algorithm                           ImageJ                                                     <https://imagej.net/>                                  RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)          Image processing software

  Software, algorithm                           Adobe Photoshop                                            <https://www.adobe.com/products/photoshop.html>        RRID:[SCR_014199](https://scicrunch.org/resolver/SCR_014199)          Image processing software

  Software, algorithm                           RStudio                                                    <http://www.rstudio.com/>                              RRID:[SCR_000432](https://scicrunch.org/resolver/SCR_000432)          Software for the R statistical computing environment

  Software, algorithm                           SGD                                                        <http://www.yeastgenome.org/>                          RRID:[SCR_004694](https://scicrunch.org/resolver/SCR_004694)          Saccharomyces Genome Database

  Software, algorithm                           R                                                          <https://www.r-project.org>                            v3.5.2 RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)   Statistical Computing Environment

  Software, algorithm                           PANTHER                                                    <http://www.geneontology.org/>                         RRID:[SCR_002811](https://scicrunch.org/resolver/SCR_002811)          Gene ontology enrichment analysis
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Where known, the Research Resource Identifiers (RRIDs) are shown.

Strains and media {#s4-1}
-----------------

All the strains used in this study are shown in the Key Resources Table, above. Unless noted otherwise, the cells were cultivated in the standard, rich, undefined medium YPD (1% ^w^/~v~ yeast extract, 2% ^w^/~v~ peptone, 2% ^w^/~v~ dextrose), at 30°C ([@bib47]). Strains (HB147 and HB171) carrying the *MET3-TAP* allele in the *rpl22aΔ*, or *rpl22bΔ*, background were generated from crosses of YSC1178-202231887 (*MET3-TAP*) with KS976 (*rpl22aΔ*), or KS979 (*rpl22bΔ*), respectively. The resulting diploids were sporulated and dissected to obtain the mutant combinations, as indicated in [Figure 5](#fig5){ref-type="fig"}. Similarly, we generated the double *rpl22aΔ, shm1Δ* (NM68); *rpl22aΔ, shm2Δ* (NM67); *rpl22aΔ, ade17Δ* (NM66) deletion mutants, shown in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}; and the *shm2Δ, ade3Δ* deletion mutants (strains NM64 and NM65), shown in [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}.

Sample-size and replicates {#s4-2}
--------------------------

For sample-size estimation no explicit power analysis was used. All the replicates in every experiment shown were biological ones, from independent cultures. A minimum of three biological replicates were analyzed in each case, as indicated in the legends of each corresponding figure. For the RNAseq and Riboseq datasets, three replicates was the minimum required for the computational pipelines for RNAseq and Riboseq datasets we used, as described below. Three replicates was also the minimum required for the robust bootstrap ANOVA, which we used in the analysis of metabolite and amino acid levels ([Figure 6](#fig6){ref-type="fig"}), and ribosome protein abundance ([Figure 2C](#fig2){ref-type="fig"}), as indicated. For measurements where at least four independent replicates were analyzed, we used non-parametric statistical methods, as indicated in each case. No data or outliers were excluded from any analysis.

SWATH-mass spectrometry {#s4-3}
-----------------------

The samples used to measure ribosomal protein abundances were from the haploid strains shown in [Figure 2](#fig2){ref-type="fig"} (see Key Resources Table). Exponentially growing cells were quenched with 100 µg/ml cycloheximide and 0.1% sodium azide. Cells were harvested from three independent cultures of each strain (5.8E+07 cells in each sample). From the same cultures, 2.5E+07 cells for each sample were harvested for amino acid analysis (see below). For SWATH-mass spectrometry, the cells were re-suspended in standard polysome buffer (20 mM Tris·Cl (pH 7.4), 150 mM NaCl, 5 mM MgCl~2~, 1 mM DTT, 100 μg/ml cycloheximide), containing 1% ^v^/~v~ Triton X-100 and 25 U/ml Turbo DNase I, to a volume of 0.35 ml. Then, 0.2 ml of 0.5 mm glass beads were added to each sample, and vortexed at maximum speed for 15 s, eight times, placing on ice for 15 s in between. The lysates were clarified by centrifuging at 5,000 rpm for 5 m, at 4°C, and again for 5 m at 13,000 rpm at 4°C. The supernatant was transferred to a 13 × 51 mm polycarbonate ultracentrifuge tube, underlaid with 0.90 ml of 1 M sucrose, and the ribosomes were pelleted by centrifugation in a TLA100.3 rotor (Beckman) at 100,000 rpm at 4°C for 1 hr. The pellets were then re-suspended in PBS, for analysis with SWATH-mass spectrometry, as described previously ([@bib84]).

All the peak area measurements are in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}. The peak area values specifically for Rpl22Ap and Rpl22Bp used as input for [Figure 2B](#fig2){ref-type="fig"} are in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"} (sheet 'RPL22_peak_areas_SWATH_MS'). The peak area values used as input for [Figure 2C](#fig2){ref-type="fig"} are in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"} (sheet 'RP_peak_areas_SWATH_MS'). To identify significant differences in the comparisons among the different strains, we used the robust bootstrap ANOVA, via the *t1waybt* function, and the posthoc tests via the *mcppb20* function, of the *WRS2* R language package ([@bib104]). For this, and all subsequent tests involving the robust bootstrap ANOVA (e.g., in the metabolite analysis), the input values for these tests were first scale-normalized so that every sample had the same total values.

HPG incorporation, microscopy, and flow cytometry {#s4-4}
-------------------------------------------------

To measure newly synthesized protein in cells (see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), we used the non-radioactive labeling assay kit 'Click-iT HPG Alexa Fluor Protein Synthesis Assay Kits', according to the manufacturer's instructions. Briefly, 50 μM of L-homopropargylglycine (HPG), an analog of methionine containing an alkyne moiety, was added to the exponentially growing yeast culture and incubated for 30 m at 30°C. The cells were fixed and permeabilized according to their instructions, and incubated with Alexa Fluor 488 containing an azide moiety, for 30 m in the dark, at room temperature. The alkyne and the azide groups undergo a CLICK reaction, and the incorporation of the HPG methionine analog was quantified by flow cytometry (Becton Dickinson Accuri C6). Mean fluorescence intensities were measured for 8,000--10,000 cells for each sample and then normalized by the mean fluorescence intensity of the wild type strain ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}).

Cells were also viewed with a Nikon Eclipse TS100 microscope, with a 100X objective, and the images were captured with a CoolSnap Dyno 4.5 Nikon camera ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). The cells were also stained with DAPI, to visualize the nuclei ([@bib3]). The exposure time for the DAPI, and GFP (to visualize HPG-Alexa incorporation), filters were 4 s, and 600 ms, respectively. All images were captured in NIS Elements Advanced Research (version 4.10) software. The fluorescent images acquired with the GFP and DAPI filters were processed identically in ImageJ and Adobe Photoshop.

Riboseq and RNAseq libraries {#s4-5}
----------------------------

We used the same approach we had described previously ([@bib10]), to collect cells from elutriated cultures of each ribosomal protein deletion and generate ribosome footprint libraries. For the RNAseq libraries from the same samples, we also used the same approach we had described ([@bib41]; [@bib10]), except that we did not select for polyA-tailed RNAs. Instead, from total RNA, we depleted rRNA, using the 'Ribo-Zero Magnetic Gold Kit (Yeast)', according to the manufacturer's instructions. All libraries were sequenced on an Illumina HiSeq4000, with multiplexing, at the Texas A and M AgriLife Genomics and Bioinformatics Facility.

Sequencing reads quality control and mapping {#s4-6}
--------------------------------------------

Raw sequencing [R]{.ul}ibosome [P]{.ul}rofiling (RP) and [T]{.ul}ranscriptional [P]{.ul}rofiling (TP) reads (50 nucleotides, nt), were subjected to quality control as follows: First, identical reads, sequencing artifacts, and sequencing adaptors were removed. Second, reads were scanned for the presence of 'N\'s'. If 'N's' were found, reads were truncated at that position, and the resulting truncated fragment was discarded. The resulting retained reads were then scanned for nucleotides whose Quality Score (Q-score) was 19 or lower. When and if found, the read in question was then truncated at that position and the resulting truncated downstream fragment was discarded. The corresponding retained fragment was then evaluated for length. Reads that were 25 nt or longer (for TP-reads) or 15 nt or longer (for RP-reads), were retained for analysis.

Reads that passed quality control were mapped to the coding exons of the *Saccharomyces cerevisiae* genome (R64-1-1 (GCA_000146045.2)), using a combination of Bowtie-directed alignment (Bowtie version 1.2.2) ([@bib51]; [@bib97]). Resulting BAM files were then processed by RSEM-Calculate-Expression (<https://github.com/deweylab/RSEM>), which provides a posterior mean and 95% credibility interval estimates for expression levels ([@bib58]). When needed, resulting alignment BAM files were sorted and indexed using the SAM Tools ([@bib55]; [@bib56]; [@bib54]) and visualized using Integrative Genome Browser (IGV) ([@bib81]; [@bib95]).

Using the same mapping pipeline, we re-mapped the reads from our previous study with wild type cells ([@bib10]). The values for the raw reads from all the strains and cell cycle points are in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}. The corresponding Transcripts Per Kilobase Million (TPM) values are in [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}. Raw sequencing data from each library have been deposited (GEO: GSE135336).

Computational pipelines for RNAseq and riboseq {#s4-7}
----------------------------------------------

To identify transcripts whose abundance was significantly different between any two strains at any of the eight different points in the cell cycle we evaluated, we used the R language packages *babel* ([@bib74]) and *DESeq2* ([@bib62]). For both packages, the raw read data ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}) were used as input. In *babel*, the number of permutations was set to ten million (nreps = 1e+07), so the minimum p-value is 1/nreps, and the minimum read count for a transcript to be included in the analysis was set to 20 ('min.rna=20'). All mRNAs with significantly different abundance between two strains, at any one point in the cell cycle, had an adjusted p-value or false discovery rate (FDR) of \<0.05 in *both* analyses, and a fold-change ≥4, and they are shown in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.

To identify transcripts with significantly altered translational efficiency, we used the R language packages *babel* and *Riborex* ([@bib57]), the last run with the *DESeq2* and with the *edgeR* ([@bib20]) platforms. Again, for all packages, the raw read data ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}) were used as input, and the minimum read count for a transcript to be included in the analysis was set to 20 ('min.rna=20' in *babel*, and 'mimiminMeanCount = 20' in *Riborex*). All mRNAs with significantly different translational efficiency between two strains, at any one point in the cell cycle, had an adjusted p-value or false discovery rate (FDR) of \<0.05 in *all* analyses, and a fold-change ≥2, and they are shown in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}.

Immunoblot analysis {#s4-8}
-------------------

For protein surveillance, protein extracts were made as described previously ([@bib2]), and run on 4--12% Tris-Glycine SDS-PAGE gels. To detect TAP-tagged Met3p with the PAP reagent, we used immunoblots from extracts of the indicated strains as we described previously ([@bib10]). Loading was evaluated with an anti-Pgk1p antibody. In each experiments several technical, repeat samples were loaded on each gel (see [Figure 5](#fig5){ref-type="fig"}).

Cell size and DNA content measurements {#s4-9}
--------------------------------------

The methods to measure the cell size of asynchronous cultures and estimate the critical size of asynchronous cultures, have been described in detail previously ([@bib32]; [@bib63]; [@bib88]; [@bib98]). DNA content was measured by flow cytometry as we described previously ([@bib38]).

Metabolic profiling {#s4-10}
-------------------

The untargeted, primary metabolite and biogenic amine analyses were done at the NIH-funded West Coast Metabolomics Center at the University of California at Davis, according to their established mass spectrometry protocols. Extract preparation was also done at the same facility, from 1E+07 cells in each sample. The cells were collected from exponentially growing cultures, quenched with 100 µg/ml cycloheximide and 0.1% sodium azide. Cells were harvested from three independent cultures of each strain (1E+07 cells in each sample), washed in water containing the same concentrations of cycloheximide and azide, and provided to the Metabolomics facility as frozen (at −80°C) pellets. To identify significant differences in the comparisons among the different strains, we used the robust bootstrap ANOVA, via the *t1waybt* function, and the posthoc tests via the *mcppb20* function, of the *WRS2* R language package ([@bib104]). The input values we used, after they were scaled-normalized for input intensities per sample, are in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}. For the primary metabolites, the data are in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"} (sheet 'pm_input'). For the biogenic amines, the data are in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"} (sheet 'ba_input'). Detected species that could not be assigned to any compound were excluded from the analysis.

Amino acid analysis {#s4-11}
-------------------

Samples for amino acid analysis were prepared as we described previously ([@bib33]), from the same cultures used for the SWATH-mass spectrometry experiments (see above), using 2.5E+07 cells for each sample. The PTH-based amino acid analyses were done at the Texas A and M Protein Chemistry Facility. Statistical tests for significant differences between the different strains were done as described above for the other metabolites. The input values we used (in nmoles), after they were normalized for total counts per sample, are in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"} (sheet 'aa_input').

Replicative lifespan assays {#s4-12}
---------------------------

All replicative lifespan assays were done on solid YPD medium, as described previously ([@bib91]).
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**Acceptance summary:**

This study provides an interesting explanation for why yeast cells lacking specific ribosomal proteins, in this case Rpl22a, have a longer lifespan. The resulting reduction in one-carbon metabolism pathway, coupled with the longer replicative lifespan in cells defective for this pathway, suggests it could be a potential target for longevity interventions.

**Decision letter after peer review:**

Thank you for submitting your article \"Translational control of one-carbon metabolism underpins ribosomal protein phenotypes in cell division and longevity\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editors and by Jessica Tyler as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This paper follows up on interesting findings that certain deletion mutants of individual ribosomal protein genes extend replicative lifespan of *Saccharomyces cerevisiae*, while others do not. They focus on the RPL22A/B paralogous gene pair, where rpl22a∆ mutants are long lived compared to WT and the rpl22b∆ mutant. Their goal was to determine the underlying mechanism of RLS extension induced by the rpl22a∆ paralog mutation. They clearly show that longevity does not correlate with doubling time, ribosome abundance or content, or critical cell size. Using carefully done riboseq analysis, the authors demonstrate downregulated translation of mRNAs related to 1C metabolism in the rpl22a∆ mutant. The reduced 1C metabolism was also supported by excellent metabolite profiling. Together, these results support the hypothesis that extended RLS in the absence of the Rpl22a paralog is correlated with reduced activity of the 1C pathway. However, the results on directly tying reduced 1C activity as causative to lifespan regulation in the rpl22a∆ mutant are not fully convincing at this time.

Essential revisions:

The reviewers identified a number of concerns that are listed below, and should be addressed through experimentation and/or rewriting where appropriate. One of the key issues was that authors are using comparisons of certain pairs of strains to make conclusions about the differences between other pairs, rather than doing direct comparisons. Streamlining the presentation is essential and should help clarify some the specific concerns.

1\) Since rpl22a deletion influences many aspects of cell physiology, it is not clear whether the lifespan-extending effect of rpl22a deletion is completely through the repression of 1-C pathways, or it is just one of the contributing factors. I would suggest additional experiments to examine the lifespans of double mutants, such as rpl22aΔ, shm1Δ and rpl22aΔ, ade1Δ. If the double mutants can further extend lifespan compared to rpl22aΔ alone, a discussion of this result would be needed.

2\) In Figure 6, the effects of shm1∆ and shm2∆ deletion mutants on RLS are modest, with the shm2 mutant only separating from BY4742 after 35 days. There is no statistical analysis provided, or an indication of whether the results were reproducible. This is a key result arguing that inhibiting 1C metabolism pathways extend RLS, so it is critical to convincingly demonstrate this.

3\) The ade17∆ mutant also extended RLS and is included as another example of a 1C mutant. However, the Ade17 enzyme is actually part of the de novo purine biosynthesis pathway. It is therefore surprising that another de novo pathway mutant, ade2∆, had no effect on RLS. How can these disparate results be reconciled?

4\) If 1C metabolism is truly mediating the effects of the rpl22a deletion, then supplementing with 1C inputs and products could potentially suppress the long RLS of the rpl22a mutant, thus supporting the overall hypothesis of the paper.

5\) In Figure 8---figure supplement 1, SHM2 translation efficiency is reduced in the rpl22a/rpl22a diploid mutant as expected from earlier figures, but now it looks like the translation efficiency is also reduced in the rpl22b/rpl22b diploid mutant, which does not have extended lifespan. This result does not seem to support the overall conclusion of specificity for the rpl22a mutant. How do the authors interpret this result? Minimally, a better explanation of the data and conclusion are needed.

6\) Related to this point, while the translational differences between rpl22aΔ and rpl22bΔ are clearly presented in Figure 4, the differences between the mutants and WT (Figure 5---figure supplement 3) are very hard to follow due to the quality of presentation. Please enlarge Figure 5---figure supplement 3 and make the gene names readable. This figure might be quite important to support the claim about quantitative differences. Also for the same point, a WT control would be needed for Figure 4C. It is clear that Met3 expression is lower in rpl22aΔ than that in rpl22bΔ, but it would be good to know how those compare to the level in WT.

7\) In Figure 8, there is clearly shown an increased cell size for an shm2∆ ade3∆ double mutant, without any significant change in DNA content, suggesting that loss of these two 1C enzymes impinges on multiple cell cycle phases. However, this is not linked back with lifespan regulation. Do shm1∆ or shm2∆ mutants also affect multiple cell cycle phases? Does this double mutant, or an ade3∆ single mutant extend RLS? The ade3∆ mutant is especially relevant because this mutation impacts both 1C and de novo purine biosynthesis, unlike the ade2 and ade17 mutants in Figure 6.

8\) The authors also investigate differences between the rpl34aΔ and rpl34bΔ deletion mutants (comparing them to WT as well), which increases complexity of the presentation without too much additional benefit. If I understand correctly, the Rpl34 strains are used as a kind of \"control\" for the RNAseq and TE experiments to verify that the assays pick up real differences between rpl22aΔ and rpl22bΔ. However, the authors also compare the Rpl34 deletion strains to WT and make remarks about them, which further complicate the whole picture and generate more questions than they answer. For example, can we conclude that 1C metabolism underlies the increased longevity of the Rpl34 mutants relative to WT? What is the importance of the differences between the Rpl22 and Rpl34 mutants described on Figure 3B and Figure 5---figure supplement 1B?

9\) The authors briefly comment that the rpl22a,bΔ strain is not long-lived (subsection "Loss of Rpl22Ap reduces overall protein synthesis"), but do not explore this observation further. What should be concluded out of this comparison? Is 1C metabolism similarly perturbed in the double deletion strain, or is Rpl22b deletion somehow \"reversing\" the effect of the lack of Rpl22a? What is the RLS of rpl22a,bΔ and how does it compare to WT?

10\) Regarding a technical aspect of the work: the authors conclude that the synchrony of their elutriated cultures is good (subsection "Generating RNAseq and Riboseq libraries from synchronous, dividing cells lacking ribosomal protein paralogs", second paragraph). However, Figure 2B shows that the budding index is starting to increase a bit too fast (compare Figure 1B of Blank et a., 2017). Also, Clb2 seems to ramp up a bit too early, and I cannot really detect a peak in Hhf1 expression. However, my main concern with the elutriation data is related to what the authors state: cells with the same volume across all mutants may very well be in different cell cycle phases (for example, G1 of rpl22aΔ is clearly longer than the G1 of the other strains). The authors compare RNAseq and TE measurements of different strains across different volumes and report genes that differ in expression even at a single time point. Yet, given the approach they follow, some of the differences they uncover could be simply caused by this shift in cell cycle phases rather than differences in expression at the same cell cycle phase. How can one make sure that the reported differences really reflect changes in cell cycle expression and not just differences in timing? Perhaps the authors could show more time series such as the one of Figure 8---figure supplement 1 (e.g. for Ade17, Shm1, Met3) to demonstrate the differences across mutants in a visually clear manner.

11\) On which criteria was the selection of 1C enzyme deletions (subsection "Genetic interventions in 1C metabolism that extend longevity") made? What is their effect on RLS compared to MET3? (i.e. what is the increase in RLS caused by MET3 deletion? Are the numbers comparable?). Does metabolomics support the fact that these deletions extend RLS through 1C metabolism?
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Author response

> Essential revisions:
>
> The reviewers identified a number of concerns that are listed below, and should be addressed through experimentation and/or rewriting where appropriate. One of the key issues was that authors are using comparisons of certain pairs of strains to make conclusions about the differences between other pairs, rather than doing direct comparisons. Streamlining the presentation is essential and should help clarify some the specific concerns.
>
> 1\) Since rpl22a deletion influences many aspects of cell physiology, it is not clear whether the lifespan-extending effect of rpl22a deletion is completely through the repression of 1-C pathways, or it is just one of the contributing factors. I would suggest additional experiments to examine the lifespans of double mutants, such as rpl22aΔ, shm1Δ and rpl22aΔ, ade1Δ. If the double mutants can further extend lifespan compared to rpl22aΔ alone, a discussion of this result would be needed.

We did this experiment, and show it in a new supplementary figure (Figure 7---figure supplement 1). We describe these results in the text:

"To test the extent to which single deletions of 1C enzymes could contribute to longevity independently of rpl22aΔ cells, we measured the longevity of rpl22aΔ cells in the context of ade17Δ, shm1Δ, or shm2Δ deletions (Figure 7---figure supplement 1). \[...\] We conclude that loss of 1C enzymes does not further extend the longevity of rpl22aΔ cells."

> 2\) In Figure 6, the effects of shm1∆ and shm2∆ deletion mutants on RLS are modest, with the shm2 mutant only separating from BY4742 after 35 days. There is no statistical analysis provided, or an indication of whether the results were reproducible. This is a key result arguing that inhibiting 1C metabolism pathways extend RLS, so it is critical to convincingly demonstrate this.

The results are significant (in every case p\<0.0001, based on the log-rank test; we added this in the legend of the figure). We added results for ade3 cells as well, as requested in a subsequent point (see revised Figure 7). As further support for the reproducibility of these effects, an independent analysis of the single mutants was performed along with double mutants combined with rpl22aΔ and lifespan extension was significant in each case for the single mutants (see Figure 7---figure supplement 1).

> 3\) The ade17∆ mutant also extended RLS and is included as another example of a 1C mutant. However, the Ade17 enzyme is actually part of the de novo purine biosynthesis pathway. It is therefore surprising that another de novo pathway mutant, ade2∆, had no effect on RLS. How can these disparate results be reconciled?

The parts of the pathway are not the same. Ade2p catalyzes a step in purine synthesis, but it is not part of one-carbon metabolism. Ade17p directly transfers 1C from folate (formyl-THF) to make IMP. Ade2p-mediated carboxylation does not involve folates. We clarified this distinction, which supports the notion that 1C, folate-based metabolism plays a key role:

"Interestingly, all three enzymes encoded by these genes, including Ade17p with its 5-aminoimidazole-4-carboxamide ribonucleotide transformylase activity, catalyze folate-dependent reactions (Tibbetts and Appling, 2000). In contrast, the carboxylase activity of Ade2p is not folate-dependent."

> 4\) If 1C metabolism is truly mediating the effects of the rpl22a deletion, then supplementing with 1C inputs and products could potentially suppress the long RLS of the rpl22a mutant, thus supporting the overall hypothesis of the paper.

We considered this approach, however, the multiple outputs and requirements of 1C metabolism cannot be corrected with simple additions of exogenous metabolites. As shown in Figure 6---figure supplement 1, supplementation with Ser, Gly, Ade, Met and combinations did not suppress the growth defect of rpl22a cells, making it unlikely that they would suppress the longevity of rpl22a cells. In contrast, loss-of-function mutations in 1C enzymes recapitulate the coordinate down-regulation of 1C metabolism in rpl22 cells and extend longevity (Figure 7). The additional experiments, suggested by the reviewers (see points 1 and 2), further support the overall hypothesis that down-regulation of 1C enzymes is responsible, at least in part, for the longer lifespan of rpl22a cells.

> 5\) In Figure 8---figure supplement 1, SHM2 translation efficiency is reduced in the rpl22a/rpl22a diploid mutant as expected from earlier figures, but now it looks like the translation efficiency is also reduced in the rpl22b/rpl22b diploid mutant, which does not have extended lifespan. This result does not seem to support the overall conclusion of specificity for the rpl22a mutant. How do the authors interpret this result? Minimally, a better explanation of the data and conclusion are needed.

We interpret these results to be consistent with our model. The confusion arises because in the (now re-numbered) Figure 8---figure supplement 1 we do not compare translational efficiencies between strains, only within each strain, at different points in the cell cycle. We added the following, to clarify this point: "Note that for the data shown in Figure 8---figure supplement 1, the translational efficiency of SHM2 is normalized against all the points in the cell cycle within each strain, not across the different strains."

> 6\) Related to this point, while the translational differences between rpl22aΔ and rpl22bΔ are clearly presented in Figure 4, the differences between the mutants and WT (Figure 5---figure supplement 3) are very hard to follow due to the quality of presentation. Please enlarge Figure 5---figure supplement 3 and make the gene names readable. This figure might be quite important to support the claim about quantitative differences. Also for the same point, a WT control would be needed for Figure 4C. It is clear that Met3 expression is lower in rpl22aΔ than that in rpl22bΔ, but it would be good to know how those compare to the level in WT.

A clearer overview with all pair-wise comparisons is in Figure 5---figure supplement 1. Regarding Figure 5---figure supplement 3, while we understand the reviewer's concern, we enlarged it somewhat, but it cannot be enlarged further. Note that we also provide all the gene names in Figure 5---source data 1. This is now mentioned in the Materials and methods and also in the legend of the figures to aid readers.

Lastly, we now added the WT control in Figure 5C. It is clear that in rpl22a cells Met3 levels are lower than in WT and in rpl22b cells. Interestingly, Met3 levels are higher in rpl22b than in WT cells.

> 7\) In Figure 8, there is clearly shown an increased cell size for an shm2∆ ade3∆ double mutant, without any significant change in DNA content, suggesting that loss of these two 1C enzymes impinges on multiple cell cycle phases. However, this is not linked back with lifespan regulation. Do shm1∆ or shm2∆ mutants also affect multiple cell cycle phases?

We made these measurements and added the following:

"We note that the cell cycle profile of wild type cells (33% of the cells in G1; Figure 8C) is not affected at all by the loss of Ade3p or Shm2p (32-33% G1 cells Figure 8C), and only slightly so by the loss of Shm1p or Ade17p (27-28% G1 cells; not shown). \[...\] It is also mild, but not severe delays in cell cycle progression that in some cases extend longevity (He et al., 2014)."

> Does this double mutant, or an ade3∆ single mutant extend RLS?

As we noted above, the double *shm1Δ,shm2Δ* mutant is lethal, and yes, *ade3Δ* alone does extend longevity (the new data was added in Figure 7).

> The ade3∆ mutant is especially relevant because this mutation impacts both 1C and de novo purine biosynthesis, unlike the ade2 and ade17 mutants in Figure 6.

See our comments and the new data we mentioned above. We also note that *ade17Δ* also impacts both 1C and de novo purine biosynthesis, and it does extend lifespan (Figure 7C).

> 8\) The authors also investigate differences between the rpl34aΔ and rpl34bΔ deletion mutants (comparing them to WT as well), which increases complexity of the presentation without too much additional benefit. If I understand correctly, the Rpl34 strains are used as a kind of \"control\" for the RNAseq and TE experiments to verify that the assays pick up real differences between rpl22aΔ and rpl22bΔ. However, the authors also compare the Rpl34 deletion strains to WT and make remarks about them, which further complicate the whole picture and generate more questions than they answer. For example, can we conclude that 1C metabolism underlies the increased longevity of the Rpl34 mutants relative to WT? What is the importance of the differences between the Rpl22 and Rpl34 mutants described on Figure 3B and Figure 5---figure supplement 1B?

We apologize for the confusion and have attempted to clarify the rationale for this analysis. The benefit and value of analyzing rpl34 mutants is that this is another paralog pair, never examined before. When we started out, the rpl34 mutants were not considered a control. Nonetheless, the data show that their transcriptomic and translatomic differences are very similar. Given that they are both long-lived, this is interesting, unlike the rpl22 pair which differ phenotypically and in the various molecular profiling assays we showed. It certainly does not contradict, and rather supports, our conclusion that longevity is associated with altered translational efficiency of specific mRNAs (we added this statement in the last paragraph of the subsection "Transcripts with altered relative translational efficiency in rpl22 and rpl34 mutants").

As for the various pairwise comparisons, we understand that it might be overwhelming, but we erred on the side of completeness. It is also valuable information. To clarify further, regarding the rpl34 mutant, we now added the following: "The down-regulation of mRNAs encoding 1C enzymes in rpl34aΔ cells is consistent with the hypothesis that down-regulation of 1C metabolism is associated with increased longevity, as we will describe later in the manuscript."

As for the rpl22 vs. rpl34 comparisons, aside from the value of showing a complete analysis, the most frequent significant changes are in 'cytoplasmic translation'. Again, given that we are dealing with ribosomal protein mutants this may not seem surprising, but it is one thing to expect something and quite another to actually show it.

> 9\) The authors briefly comment that the rpl22a,bΔ strain is not long-lived (subsection "Loss of Rpl22Ap reduces overall protein synthesis"), but do not explore this observation further. What should be concluded out of this comparison? Is 1C metabolism similarly perturbed in the double deletion strain, or is Rpl22b deletion somehow \"reversing\" the effect of the lack of Rpl22a? What is the RLS of rpl22a,bΔ and how does it compare to WT?

All the RLS data for the double rpl22 mutant (not long-lived) have been reported (in Steffen et al., 2012), as we cite. Here, we only used rpl22ab cells in our measurements of ribosome composition (Figure 2) and protein synthesis rates (Figure 2---figure supplement 1). The point Figure 2 makes, is that Rpl22 perturbations, including the complete lack of it in rpl22ab cells, does not change ribosome composition, as we state: "In all strains tested, including the rpl22a,bΔ cells lacking Rpl22 altogether, the relative proportion of the RPs in ribosomes was essentially constant, indicated by the Spearman rank correlation coefficients (ρ), which were very high (≥0.95) in each case."

Likewise, for the protein synthesis measurements we showed (Figure 2---figure supplement 1), we state: "Because rpl22a,bΔ cells are not long-lived (Steffen et al., 2012), we conclude that merely reducing rates of protein synthesis is not sufficient to promote longevity. This conclusion is in agreement with the observation that inhibiting protein synthesis with cycloheximide also does not increase lifespan (Steffen et al., 2008)."

We did not do ribosome profiling of rpl22ab cells, and we cannot comment on any specific pathways, including 1C metabolism, in these cells. However, even if we had done those extensive experiments we wouldn't know how to interpret them with regards to longevity. The double mutant has a strong growth defect (proliferates slower than rpl22a cells, see Figure 2). Even if 1C metabolism is down-regulated in these cells, it is not clear to us how one can draw conclusions about longer lifespan from a mutant that grows poorly and it is not long-lived. Instead, all the signatures we report implicating 1C metabolism were made from long-lived mutants.

> 10\) Regarding a technical aspect of the work: the authors conclude that the synchrony of their elutriated cultures is good (subsection "Generating RNAseq and Riboseq libraries from synchronous, dividing cells lacking ribosomal protein paralogs", second paragraph). However, Figure 2B shows that the budding index is starting to increase a bit too fast (compare Figure 1B of Blank et al., 2017). Also, Clb2 seems to ramp up a bit too early, and I cannot really detect a peak in Hhf1 expression. However, my main concern with the elutriation data is related to what the authors state: cells with the same volume across all mutants may very well be in different cell cycle phases (for example, G1 of rpl22aΔ is clearly longer than the G1 of the other strains). The authors compare RNAseq and TE measurements of different strains across different volumes and report genes that differ in expression even at a single time point. Yet, given the approach they follow, some of the differences they uncover could be simply caused by this shift in cell cycle phases rather than differences in expression at the same cell cycle phase. How can one make sure that the reported differences really reflect changes in cell cycle expression and not just differences in timing? Perhaps the authors could show more time series such as the one of Figure 8---figure supplement 1 (e.g. for Ade17, Shm1, Met3) to demonstrate the differences across mutants in a visually clear manner.

Unfortunately, for the ribosome profiling experiments it is not possible to extrapolate "time-points" from cell size points, due to different strains with different doubling time. It can also lead to artifacts when elutriated cultures are analyzed, even if we were dealing with one strain. All elutriations, even when aliquots are followed from the same elutriated sample at different time points (we present some of those, see Figure 8), should always be normalized on the basis of size. Specifically for the figure the reviewer comments on, we have done our ribosome profiling from cell-size series, from pools of cells collected at the same cell size. That is the only way we could obtain enough cells to do our ribosome profiling, as we had done in our prior study (Blank et al., 2017). Furthermore, the different series for the different strains are directly comparable to each other on the basis of size. For a study that seeks to uncover growth-related effects (through protein synthesis), we view this as an advantage. Lastly, regarding the magnitude of the increase in cell cycle transcripts (e.g., for histones), we note that the scale of the axis is in Log2 values. We also kept the scale the same for all panels. This may make the magnitude of the effect to appear smaller in histones vs. CLB2, but is still evident when one compares histones vs. actin. For these reasons, we respectfully disagree that this is a concern.

> 11\) On which criteria was the selection of 1C enzyme deletions (subsection "Genetic interventions in 1C metabolism that extend longevity") made?

We now added the following: "ADE17 and SHM2 encode 1C enzymes and they were translationally down-regulated in rpl22aΔ cells. ADE2 does not encode a 1C enzyme and its translational efficiency did not change in rpl22aΔ vs. rpl22bΔ cells. We also tested shm1Δ cells, because even though the translational efficiency of SHM1 was similar in rpl22aΔ vs. rpl22bΔ cells, Shm1p catalyzes in mitochondria the same reaction that Shm2p does in the cytoplasm."

> What is their effect on RLS compared to MET3? (i.e. what is the increase in RLS caused by MET3 deletion? Are the numbers comparable?).

We thank the reviewer for this suggestion. Yes, the lifespan extension upon loss of Met3p is \~15%, and similar to the magnitude of the lifespan extension in shm1, shm2 or ade17 deletions. We added the following: "We note that loss of Met3p leads to a similar magnitude (≈15%) of lifespan extension (McCormick et al., 2015)."

> Does metabolomics support the fact that these deletions extend RLS through 1C metabolism?

There is literature reporting various metabolic perturbations of 1C metabolites, but that is not surprising given that the corresponding enzymes (Shm1, Shm2, Ade17) are core players of 1C metabolism. We are not sure how to interpret the reviewer's question whether they 'support the fact that these deletions extend RLS through 1C metabolism'. We also note that metabolomic analyses of log phase cells must be interpreted extremely cautiously when considering potential effects on replicative aging, as old cells represent an extremely small fraction (roughly 1/(2\^n) where n represents age) of a log phase population.
